Test Price
2,800 AED✅ Home Collection Available
FAT1 Gene Sequencing (Facioscapulohumeral Dystrophy‑like Phenotype) – 2,800 AED in Dubai, UAE
Executive Summary & Core Metrics
This advanced genetic analysis uses Next‑Generation Sequencing (NGS) to detect pathogenic variants in the FAT1 gene associated with a facioscapulohumeral muscular dystrophy‑like (FSHD‑like) phenotype. The test provides definitive molecular confirmation with 99.9% diagnostic sensitivity through ISO‑accredited processing.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited NGS processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by a certified genetic counsellor.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The FAT1 gene sequencing test uses Next‑Generation Sequencing (NGS) to analyze the entire coding region and intronic boundaries, including copy number variation (CNV) analysis. This comprehensive approach achieves a diagnostic sensitivity of 99.9% and covers deep intronic and regulatory regions that traditional Sanger sequencing may miss.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Methodology | NGS – full gene sequencing with CNV analysis | Single‑gene Sanger sequencing (limited to point mutations) |
| Diagnostic Precision | 99.9% sensitivity; covers deep intronic and regulatory regions | ~95% sensitivity; misses large deletions/duplications |
| Turnaround Time | 3–4 weeks (ISO‑accredited cold‑chain logistics) | 4–6 weeks (often delayed due to batch processing) |
| Post‑Test Support | Telephonic clinical interpretation & genetic counselling | Minimal interpretive guidance |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant in Medical Genetics, I emphasize that a positive FAT1 variant requires careful correlation with clinical phenotype and family history. This test provides a definitive molecular diagnosis, guiding surveillance and family planning. Always discuss results with a genetics specialist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue any prescribed medication without consulting your treating physician. Genetic test results do not replace ongoing clinical management.
Safety Exclusion Criteria & Emergency Red Flags
- Active acute illness with fever or systemic infection – postpone collection until recovery.
- Known bleeding disorder or therapeutic anticoagulation not previously cleared by a physician.
- Unstable cardiorespiratory status preventing safe phlebotomy.
- Emergency Red Flags: Sudden onset of severe muscle weakness, difficulty swallowing (dysphagia), or respiratory distress – seek immediate hospital care; reporting to Emergency Room is mandatory irrespective of test scheduling.
Patient FAQ & Clinical Guidance
1. What does the FAT1 gene test detect and why is it important?
This test identifies DNA variants in the entire FAT1 gene that can cause a facioscapulohumeral muscular dystrophy‑like condition, helping to establish a definitive molecular diagnosis and guide family planning.
2. How is the sample collected and is it painful?
A small blood draw from the arm or a single drop on an FTA card is all that is needed; the procedure is quick, minimally uncomfortable, and performed by a DHA‑licensed phlebotomist at your home.
3. How long will it take to receive results and what support is offered afterwards?
Results are typically ready within 3 to 4 weeks; you will receive a telephonic consultation with a clinical expert to explain the findings and discuss next steps.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This test adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. Laboratory processing is performed under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139). All clinical interpretations are provided by a DHA‑licensed physician. DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | FAT1 Gene Sequencing (Facioscapulohumeral Dystrophy‑like Phenotype) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral Whole Blood or FTA Card (DNA) |
| Methodology Used | Next‑Generation Sequencing (NGS) with CNV analysis |
| ICD-10-CM Code | G71.0 (Facioscapulohumeral muscular dystrophy) |
| LOINC Code | 81247-9 (Genetic analysis) |
| DHA Facility License & Laboratory Address Invariants | DHA Facility License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Operated by DNA Labs UAE. |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians